Inflammatix

Inflammatix is a molecular diagnostics company reimagining diagnostics by reading the immune system to deliver rapid results, improving patient care and alleviating major public health burdens. The company’s initial focus is on acute infections and sepsis, with tests that combine proprietary biomarkers and advanced machine learning capabilities to help physicians quickly provide the right treatment for the right patients. Future tests will run on the company's sample-to-answer instrument platform, Myrna TM, enabling precision medicine capabilities at the point of care in less than 30 minutes.